Inter Pharma’s Earnings Double to THB105 million in 2021

Inter Pharma Public Company Limited (SET: IP) announced its 2021 consolidated financial statement through the Stock Exchange of Thailand as follows;

Yearly 2021 2020
Net Profit (Loss)
Million Baht
105.215 52.536
Earning Per Share (Baht) 0.36 0.182
% Change 100.27

 

IP reported a net profit of THB105 million in 2021, an increase of 100.27% from a net profit of THB52 million in 2020. 

Total revenue amounted to THB920.98 million. Almost all of the revenues were sales revenue which amounted to THB908.63 million or 98.66% of total income, increasing from the same period of the previous year by THB466.53 million or 105.53%. This is due to an increase in revenue from sales of Human Wellness & Anti- Aging products from THB245.50 million in 2020 to THB572.42 million in 2021, increasing by THB324.78 million or 132.29% year-on-year.  

Increment of revenue was mainly derived from the sales of various products such as in Probiotic products which increased by THB51.87 million or 41.37%year-on-year, Fit Serie products increased by THB53.22 million year-on-year and income from sales of other products of the Company such as Probac Ultra Collagen, Multivitamins products,and other supplement products (Vitahealth),  etc.

In addition, there has been an increase in revenue from sales of Animal Healthcare products in 2020 amounting from THB196.60 million to THB336.21 million or an increase of THB139.61 million or 71.01% in 2021. Main contribution to revenue increment was from the sale of animal snacks under Choo Choo Brand amounted of THB12.72 million, pet food products under Maria Brand which amounted to THB15.06 million, animal drugs amounted to THB23.82 million and Feed additive products amounted of THB75.21 million. 

During 2021, the company had successfully acquired Teva’s pharmaceutical manufacturing factory in Ayutthaya on August 11th, 2021, which enable the company to recognize additional revenue from sales of generic drug products of THB67.78 million.

 

In addition, the Board of Directors approved the omission of dividend payment for the operating results of the year 2021, due to the company has plan for business expansion. Therefore, reserves must be set aside to support the expansion plan in order to create sustainable growth for the company.